Literature DB >> 3309809

[Comparative pharmacokinetics of fosfomycin in the neonate: 2 modes of administration].

M Guibert1, J F Magny, F Poudenx, L Lebrun, M Dehan.   

Abstract

In newborn, fosfomycin-cefotaxime in combination is more and more commonly used for the treatment of nosocomial infections. A pharmacokinetic study was conducted in ten newborns in the aim of suggesting a therapeutic schedule of the fosfomycin. Each newborn received 200 mg/kg, intravenously twice a day. Two groups have been formed according to the time of perfusion: 2 h or 30 min. The study of pharmacokinetic parameters do not demonstrated significant difference between the two populations. In addition, residual serum concentrations, twelve hours after the administration, are greater than the minimal inhibitory concentrations of most common pathogens causing nosocomial infections in neonates.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3309809

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  3 in total

Review 1.  The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.

Authors:  Grace Li; Joseph F Standing; Julia Bielicki; William Hope; John van den Anker; Paul T Heath; Mike Sharland
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

2.  IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis.

Authors:  Zoe Kane; Silke Gastine; Christina Obiero; Phoebe Williams; Sheila Murunga; Johnstone Thitiri; Sally Ellis; Erika Correia; Borna Nyaoke; Karin Kipper; John van den Anker; Mike Sharland; James A Berkley; Joseph F Standing
Journal:  J Antimicrob Chemother       Date:  2021-06-18       Impact factor: 5.790

Review 3.  Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.

Authors:  Christopher A Darlow; Renata M A da Costa; Sally Ellis; François Franceschi; Mike Sharland; Laura Piddock; Shampa Das; William Hope
Journal:  Paediatr Drugs       Date:  2021-08-26       Impact factor: 3.022

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.